7210 Wareham Drive, Tampa, FL 33647
Sept. 19, 2024 Lindora Clinics, a long-time competitor in the medical weight loss market, has begun selling franchises. The firm has 31 sites, focused on the California market, but plans to expand nationally via franchising. Lindora franchisees’ gross revenue can vary, but the data provided in the brand’s 2024 FDD offers insight into potential earnings, […]
Lindora Clinics Now Selling Franchises Read More »
Sept. 12, 2024 Noom is the latest weight loss company to start prescribing compounded versions of the obesity medication semaglutide. This follows similar moves by Hims, Ro, and other telehealth companies capitalizing on shortages of brand-name obesity drugs. Noom will sell the compounded GLP-1 drug starting at $149 a month, it says. The company, which
Noom Offers Compounded Weight Loss Drugs Read More »
August 14, 2024 Nearly half of online pharmacies that sell semaglutide — the active ingredient in Ozempic and Wegovy — are doing so illegally, posing safety risks for consumers, according to a study published Aug. 2 in JAMA Network Open. Of the 317 online pharmacies included in the study, researchers found 42.27% were operating illegally, meaning
Study finds that 42% of online pharmacies selling semaglutide are illegal Read More »
August 13, 2024 As reported by Fiercehealthcare.com today in an article… The genetic testing company 23andMe sees an opportunity to get in on the weight loss boom. The company, through its Lemonaid Health business, plans to launch a GLP-1 weight loss telehealth membership by the end of the month, it announced last week along with
23 and me To Enter The Weight Loss Market Read More »
August 8, 2024 A Financial Times article reported that… “Eli Lilly chief executive David Ricks said the better than expected sales in its most recent quarter were driven by the GLP-1 medicines as the drugmaker “advanced our manufacturing expansion agenda” to meet the huge demand for the medicines. Increased pricing power for Mounjaro also boosted
Eli Lilly Posts Strong Weight Loss Drug Sales Read More »
August 5, 2024 Wellness company Medifast (NYSE:MED) fell short of analysts’ expectations. Management said that: “We are acting decisively to transform our business to position us for long-term growth, with a strong balance sheet free of debt, a clear focus on new customer acquisition, and a broader health and wellness offer to a significantly expanded
Medifast Reports Q2 Results Read More »
August 1, 2024 In August, Certificates of Analysis on the compounded GLP-1 medications available through Hims & Hers will be accessible to customers, in an effort to introduce a higher level of transparency that helps our customers understand what is in the medications they receive, as well as how to understand the high quality standards
Hims & Hers To Offer Certificates of Analysis for Compounded GLP-1s Read More »
August 1, 2024 Management reported that: “WeightWatchers has the right strategy to return the business to growth. With a rapidly changing landscape, we are taking decisive actions to navigate through this environment and completely reimagining how we operate,” said Sima Sistani, the Company’s CEO. “We are executing a significant streamlining of our operational structure, to
Weight Watchers Reports Q2 Results Read More »
July 11, 2024 An article by Endpoints.com cited a study that found that only about 15% of people who began taking GLP-1 drugs such as Wegovy stuck with them after two years, according to a new analysis by pharmacy benefit manager Prime Therapeutics. Prime, which is owned by a group of Blue Cross Blue Shield
Nearly all patients quit weight loss shots within two years, study finds Read More »
June 13, 2024 Just 33% of employers and health plans cover the drugs for obesity, according to a report published Tuesday by consultant firm Pharmaceutical Strategies Group. The biggest reason? The drugs’ high costs. “Affordability is the main challenge, and we have seen a few employers offer coverage, then pull back after they evaluated the
Employers and Insurers Push Back on GLP-1 Drugs Coverage Read More »